Cyclin-dependent kinases in cancer: Role, regulation, and therapeutic targeting
Source : https://www.sciencedirect.com/science/article/abs/pii/S1876162323000135?via=ihub
Regulated cell division is one of the fundamental phenomena which is the basis of all life on earth. Even a single base pair mutation in DNA leads to the production...
Conclusions/Relevance: In this chapter, we discuss the molecular mechanism through which cyclins and CDKs regulate cell cycle progression and the emergence of cyclins and CDKs as rational targets in cancer. We also discuss recent advances in developing CDK inhibitors, which have emerged as a novel class of inhibitors, and their associated...
Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37038927/
The therapeutic paradigm of breast cancer involving CDK4/6 inhibitors presents some still open discussion points. Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer and the...
Expert opinion: The therapeutic paradigm of breast cancer involving CDK4/6 inhibitors presents some still open discussion points. Further evidence regarding the best treatment strategy in HR+ HER2- metastatic breast cancer and the efficacy of CDK 4/6is in the early stage will be necessary in the next future. Predictive biomarkers of response...
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-023-02471-8
Introduction Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in...
Conclusion: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.
-
Albert Dekker3yrmales always have more advanced disease
Economic evaluation for palbociclib plus fulvestrant | TCRM
Since there are no direct evidence from head-to-head clinical trials, in order to determine relative efficacy of treatments, indirect treatment comparison (ITC) methods can be used. Higher overall survival (OS)...
Conclusion: From the Italian perspective, a cost-saving profile associated with the use of PAL+FUL for the management of advanced/metastatic HR+/HER2- breast cancer compared to RIB+FUL and ABM+FUL emerged.
-
Albert Dekker3yrnot sure how that is possible may be they used lower doses
Association between cyclin-dependent kinase 4/6 inhibitors and venous thromboembolism: analysis of F.A.E.R.S. data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34581647/
Although it is not able to confirm the casual relationship between VTE and CDK4/6 inhibitors, this study suggested signal of VTE reporting in patients receiving CDK4/6 inhibitors, which is likely...
Conclusions: Although it is not able to confirm the casual relationship between VTE and CDK4/6 inhibitors, this study suggested signal of VTE reporting in patients receiving CDK4/6 inhibitors, which is likely to reflect a potential association. The results may enhance physicians' awareness of the potential side effect of VTE associated...
-
Albert Dekker3yrwe all had patients who had it and typically 1-3 months after start